Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:13:00.495Z.
Calculation as of: 2026-10-06T15:13:00.495Z.
Quote observation: 2026-10-06T15:10:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880fb47a961da82dee7b372bf013e19f9356fddf046c7e26e64914405e113cb3
PE RATIO
N/A
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$259.91M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$266.10M
PE Ratio
N/A
TTM Avg
16.07
3Y Avg
13.93
5Y Avg
35.67
Market Cap
$266.79M
PE Ratio
N/A
TTM Avg
15.73
3Y Avg
15.73
5Y Avg
15.86
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $259.91M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.09M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $262.66M | N/A | 14.47 | 14.47 | 17.60 |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | N/A | 4.44 | 4.44 | 4.44 |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.48M | N/A | 83.73 | 30.92 | 28.56 |
| OraSure Technologies, Inc. (OSUR)vs › | $266.10M | N/A | 16.07 | 13.93 | 35.67 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.17M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $266.79M | N/A | 15.73 | 15.73 | 15.86 |
| Invivyd, Inc. (IVVD)vs › | $246.29M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$3.31
Forward EPS (Est.)
$-1.19
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
